Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NA-miR-128-3p
- Development stage
- Preclinical
- Lead developer
- Zhejiang University
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**NA-miR-128-3p** is a preclinical, targeted sustained-release chitosan nanoparticle formulation containing a miR-128-3p agomir. It was developed by researchers at Zhejiang University for hepatocellular carcinoma. The self-assembled nanoparticle uses chitosan hydrochloride and pentasodium tripolyphosphate as the delivery matrix and incorporates a targeting aptamer to protect and deliver the miRNA mimic. By restoring miR-128-3p activity, the formulation suppresses AKT1 expression and inhibits hepatocellular carcinoma progression. In cellular and mouse xenograft experiments, NA-miR-128-3p showed antitumor activity and enhanced the activity of separately administered oroxin B through effects involving PI3K-AKT and VEGF signaling.
- Other names
- chitosan-based targeted sustained-release nanoparticle delivery miR-128-3p agomirNA-miR-128–3p
02
Targets
ADAM28 (Disintegrin and metalloproteinase domain-containing protein 28)PARK7 (Protein deglycase DJ-1)SLC16A1 (Mitochondrial Pyruvate Carrier)PDK (Pyruvate dehydrogenase kinase isoform 1)Neuronal pentraxin 1 mRNA
Beyond the preview
Go deeper on NA-miR-128-3p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NA-miR-128-3p.